Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
The collaboration aims to enhance the accuracy of physics-based methods with AI models for optimising small molecule medicine discovery and development
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
In light of the contributions of these three institutes, it was decided to organize a CSIR Startup Conclave in Hyderabad. The event, scheduled for April 22–23, 2025
Findings likely to generate hypotheses about potential new uses of drugs
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Aurigene.AI is an end-to-end solution for small molecule drug discovery
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Atlas AI combines NVIDIA BioNeMo cloud APIs for intelligent chemical and protein design
Subscribe To Our Newsletter & Stay Updated
